Pfizer (PFE) closed the last trading session at $22.79, gaining 1.3% over the past four weeks, but there could be plenty of ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...